A rational, systematic approach for the development of vaccine formulations. - Wikidata - awgldk - TriplyDB

A rational, systematic approach for the development of vaccine formulations.

A rational, systematic approach for the development of vaccine formulations.

http://www.wikidata.org/entity/Q37846559

about

Particulate inorganic adjuvants: recent developments and future outlook.Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.

P2860

Q38286377-DB46048F-0127-4CBE-B79F-97FD4B6FF3FC Q38678186-47AB23AD-1D80-418D-99AA-7A4374B897ED

P2860

A rational, systematic approach for the development of vaccine formulations.

http://www.wikidata.org/entity/Q37846559

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A rational, systematic approach for the development of vaccine formulations.

@en

A rational, systematic approach for the development of vaccine formulations.

@nl

type

label

A rational, systematic approach for the development of vaccine formulations.

@en

A rational, systematic approach for the development of vaccine formulations.

@nl

prefLabel

A rational, systematic approach for the development of vaccine formulations.

@en

A rational, systematic approach for the development of vaccine formulations.

@nl

P1433

Q37846559-4E951D96-2229-4210-A248-11F58137DD79

P1476

Q37846559-41A6733B-1ED6-4F32-9D05-5900457AE92A

P2093

Q37846559-4088DE2A-F0F3-4041-84A0-023C5B2BB540

P2860

Q37846559-032263C0-2F92-4F9D-A00E-5EA348AD03BE

Q37846559-1277EC93-EC51-45AA-9CAA-AF3F5AB1953F

Q37846559-151B39FF-B198-4C61-B489-D94921C6EF09

Q37846559-1885C0E3-CA88-4078-8348-6BC5338E0761

Q37846559-1B51EBBF-E8C8-405C-8CA2-9CA4EC9265E6

Q37846559-1F4F2850-300F-4CBD-914B-5CCEFCE2FA03

Q37846559-2066D1CA-236D-4C74-9141-DDD22FF77921

Q37846559-236535EA-C442-4720-AD40-7EA5129D88AB

Q37846559-24836F45-18AD-443C-9ACA-D43CE2A280C1

Q37846559-2D35D8B7-A050-461E-8A38-7DA237E5E7D4

P2888

Q37846559-5321AE39-63ED-477C-8AC2-36D8E9A02383

P304

Q37846559-8E17B983-C0F3-4AE3-91BA-96194327B45B

P31

Q37846559-4548715C-6E47-45F0-A419-0AF4B374C1B1

P356

Q37846559-B4D0C131-0C01-4A39-849C-8E1C3DC34C24

P407

Q37846559-375C580C-1B47-4460-BB2E-FAFEE9D6A10D

P433

Q37846559-CDB290B7-CA41-469D-9CD8-8C22FCE09224

P478

Q37846559-293F5A7F-997E-4EEC-B955-0D10516429A0

P577

Q37846559-CBBC226C-FFCA-42D3-A7A5-8EEFD3DFBE2D

P5875

Q37846559-2140DFD0-78C9-4D9C-948A-7A3043BDD28D

P6179

Q37846559-0E5D0791-7AE7-4CAF-A0E6-9451A4646215

P698

Q37846559-487E54DC-67EE-4AC6-B9EF-8C39F97F5F05

P932

Q37846559-9060267C-F402-4B40-95D6-2C4DA5706F05

P356

S12248-011-9261-1

P1433

The AAPS Journal

P1476

A rational, systematic approach for the development of vaccine formulations.

@en

P2093

Garry L Morefield

http://www.w3.org/2001/XMLSchema#string

P2860

Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

Molecular and cellular signatures of human vaccine adjuvants.

Emulsion-based adjuvants for influenza vaccines.

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

P2888

s12248-011-9261-1

P304

191-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-011-9261-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49968282

http://www.w3.org/2001/XMLSchema#string

P6179

1022148004

http://www.w3.org/2001/XMLSchema#string

P698

21347616

http://www.w3.org/2001/XMLSchema#string

P932

3085699

http://www.w3.org/2001/XMLSchema#string